MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial - Nature

As presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAGE-A8 peptide presented by HLA-A*02:01—encouraging safety and a preliminary efficac…